Molecular Partners AG
Index- P/E1.57 EPS (ttm)3.86 Insider Own- Shs Outstand32.53M Perf Week1.65%
Market Cap209.70M Forward P/E- EPS next Y-2.02 Insider Trans- Shs Float18.68M Perf Month0.10%
Income128.60M PEG- EPS next Q- Inst Own3.00% Short Float / Ratio0.08% / 6.43 Perf Quarter-7.82%
Sales206.90M P/S1.01 EPS this Y276.40% Inst Trans-1.04% Short Interest0.02M Perf Half Y-3.22%
Book/sh7.89 P/B0.77 EPS next Y-154.00% ROA- Target Price14.33 Perf Year-70.37%
Cash/sh7.83 P/C0.77 EPS next 5Y- ROE- 52W Range5.50 - 21.80 Perf YTD-7.82%
Dividend- P/FCF- EPS past 5Y- ROI48.60% 52W High-72.30% Beta-
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low9.78% ATR0.19
Employees175 Current Ratio14.80 Sales Q/Q-3.80% Oper. Margin- RSI (14)47.81 Volatility0.38% 2.61%
OptionableNo Debt/Eq0.02 EPS Q/Q-1.10% Profit Margin- Rel Volume0.12 Prev Close6.00
ShortableYes LT Debt/Eq0.02 EarningsMar 09 AMC Payout0.00% Avg Volume2.43K Price6.04
Recom2.70 SMA20-0.11% SMA50-5.48% SMA200-7.10% Volume286 Change0.63%
Aug-30-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-29-22Downgrade SVB Leerink Outperform → Mkt Perform $30 → $8
May-25-22Upgrade Credit Suisse Underperform → Neutral
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
Mar-13-23 09:30AM
Mar-11-23 02:14AM
Mar-09-23 04:00PM
Mar-02-23 04:00PM
01:15AM Loading…
Feb-28-23 01:15AM
Feb-10-23 01:00AM
Jan-16-23 01:00AM
Jan-12-23 06:18AM
Jan-08-23 03:00PM
Dec-30-22 01:00AM
Dec-12-22 07:00PM
Dec-01-22 11:46PM
Nov-10-22 01:00AM
Nov-04-22 09:39AM
12:30PM Loading…
Nov-03-22 12:30PM
Nov-02-22 12:30PM
Oct-27-22 04:00PM
Aug-25-22 04:30PM
Aug-18-22 01:00AM
Jul-21-22 11:30AM
Jun-10-22 01:00AM
May-12-22 04:05PM
May-11-22 01:00AM
May-03-22 12:00PM
Apr-27-22 08:02AM
Apr-26-22 04:05PM
02:00PM Loading…
Apr-23-22 01:00AM
Apr-13-22 12:00PM
Mar-24-22 02:00AM
Mar-17-22 01:00AM
Mar-15-22 04:30PM
Feb-25-22 04:30PM
Feb-11-22 04:10PM
Feb-10-22 07:13AM
Jan-28-22 05:57AM
Jan-23-22 02:28AM
Jan-18-22 01:00AM
Jan-13-22 05:00PM
Jan-12-22 10:13AM
Jan-11-22 11:37AM
Jan-10-22 06:51PM
Jan-06-22 10:00AM
Jan-05-22 04:05PM
Dec-15-21 01:00AM
Dec-14-21 12:16PM
Dec-12-21 04:00PM
Dec-09-21 01:00AM
Dec-06-21 01:00AM
Dec-03-21 01:00AM
Nov-30-21 12:48PM
Nov-24-21 01:00AM
Nov-16-21 06:49AM
Nov-04-21 02:00AM
Oct-28-21 01:00AM
Oct-20-21 01:00AM
Sep-03-21 04:05PM
Aug-26-21 01:00AM
Aug-09-21 01:00AM
Jul-13-21 06:55AM
Jul-08-21 09:04AM
Jun-15-21 10:00PM
Jun-13-21 04:00PM
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.